Efficacy and safety of adjunctive antiseizure medications for dravet syndrome: A systematic review and network meta-analysis

Purpose: Recently, the U.S. Food and Drug Administration (FDA) approved stiripentol, cannabidiol, and fenfluramine to treat patients with Dravet syndrome (DS). Moreover, soticlestat was determined as a promising new drug for the treatment of DS as it has good efficacy and safety. However, the effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jianhua, Zhang, Liu, Zhou, Xi, Wang, Jiajun, Zheng, Xiangyi, Hu, Hankun, Wu, Dongfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471196/
https://www.ncbi.nlm.nih.gov/pubmed/36120377
http://dx.doi.org/10.3389/fphar.2022.980937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471196/
https://www.ncbi.nlm.nih.gov/pubmed/36120377
http://dx.doi.org/10.3389/fphar.2022.980937

Ejemplares similares